← Back to Screener
Oric Pharmaceuticals, Inc. Common Stock (ORIC)
Price$10.89
Favorite Metrics
Price vs S&P 500 (26W)-30.17%
Price vs S&P 500 (4W)-13.17%
Market Capitalization$1.08B
All Metrics
Book Value / Share (Quarterly)$3.90
P/TBV (Annual)1.84x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.13
Price vs S&P 500 (YTD)27.28%
EPS (TTM)$-1.51
10-Day Avg Trading Volume1.75M
EPS Excl Extra (TTM)$-1.51
EPS (Annual)$-1.47
ROI (Annual)-33.68%
Cash / Share (Quarterly)$2.86
ROA (Last FY)-31.66%
EBITD / Share (TTM)$-1.62
ROE (5Y Avg)-40.02%
Cash Flow / Share (Annual)$-1.13
P/B Ratio2.81x
P/B Ratio (Quarterly)2.07x
Net Income / Employee (Annual)$-1
ROA (TTM)-36.22%
EPS Incl Extra (Annual)$-1.47
Current Ratio (Annual)14.13x
Quick Ratio (Quarterly)13.79x
3-Month Avg Trading Volume1.85M
52-Week Price Return129.21%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$4.54
52-Week High$14.93
EPS Excl Extra (Annual)$-1.47
CapEx CAGR (5Y)1.22%
26-Week Price Return-21.42%
Quick Ratio (Annual)13.79x
13-Week Price Return-4.44%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)14.13x
Enterprise Value$1,033.182
Book Value / Share Growth (5Y)-13.15%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$2.86
3-Month Return Std Dev120.30%
Net Income / Employee (TTM)$-1
ROE (Last FY)-33.68%
EPS Basic Excl Extra (Annual)$-1.47
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.51
ROI (TTM)-38.79%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$4.93
Price vs S&P 500 (52W)94.12%
Year-to-Date Return31.42%
5-Day Price Return3.37%
EPS Normalized (Annual)$-1.47
ROA (5Y Avg)-36.13%
Month-to-Date Return-15.15%
Cash Flow / Share (TTM)$-1.96
EBITD / Share (Annual)$-1.61
ROI (5Y Avg)-40.02%
EPS Basic Excl Extra (TTM)$-1.51
P/TBV (Quarterly)1.65x
P/B Ratio (Annual)2.07x
Book Value / Share (Annual)$3.90
Price vs S&P 500 (13W)-7.31%
Beta1.17x
Revenue / Share (TTM)$0.00
ROE (TTM)-38.79%
52-Week Low$4.52
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.35
4.33
4.33
4.33
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ORICOric Pharmaceuticals, Inc. Common Stock | — | — | — | — | $10.89 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies designed to overcome cancer resistance mechanisms across three focus areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company's pipeline includes product candidates ORIC-944, ORIC-114, and ORIC-533.